Show Filters

Searches all publications.

Search Fulltext



Select publication to see the relevant sections.

Publication Date

    E.g., 2018-02-25
    E.g., 2018-02-25


49993 items
1:22 PM, Feb 22, 2018  |  BC Extra | Clinical News

Novo's oral GLP-1 analog meets in first Phase IIIa for Type II diabetes

Novo Nordisk A/S (CSE:NOVOB; NYSE:NVO) said oral semaglutide met the primary endpoint in the Phase IIIa PIONEER 1 trial to treat Type II diabetes. The candidate is on track to be the first approved oral...
12:03 PM, Feb 22, 2018  |  BC Extra | Financial News

Ascendis, Aimmune price upsized follow-ons

Endocrinology company Ascendis Pharma A/S (NASDAQ:ASND) and allergy play Aimmune Therapeutics Inc. (NASDAQ:AIMT) raised a total of $401 million late Wednesday in bumped-up follow-ons. Ascendis raised $225 million through the sale of 3.9 million ADSs at...
11:31 AM, Feb 22, 2018  |  BC Extra | Company News

Positive CHMP vote likely for Clovis' PARP inhibitor

Clovis Oncology Inc. (NASDAQ:CLVS) rose $4.95 to $59.88 on Thursday after it said EMA's CHMP communicated a "positive trend vote" for an MAA for rucaparib (CO-338) to treat platinum-sensitive, BRCA-mutant advanced ovarian cancer. Clovis expects...
3:02 AM, Feb 22, 2018  |  BC Extra | Financial News

Kallyope raises $66M in series B

Kallyope Inc. (New York, N.Y.) raised $66 million in a series B round. Existing investors Lux Capital, The Column Group, Polaris Partners, Illumina Ventures and Alexandria Venture Investments participated, as did new investors Euclidean Capital...
5:03 PM, Feb 21, 2018  |  BC Extra | Company News

United Therapeutics slips on further delays for RemoSynch

United Therapeutics Corp. (NASDAQ:UTHR) fell $12.79 to $122.17, losing $553 million in market cap, after reporting during its 4Q17 earnings call Wednesday that RemoSynch, the implantable drug infusion system for Remodulin treprostinil, will launch "within...
4:55 PM, Feb 21, 2018  |  BC Extra | Politics & Policy

Trump Administration outlines plans for Medicare, Medicaid reforms

The Trump Administration outlined a plan to reform Medicaid and Medicare and reduce "free-riding" by foreign markets in the joint Economic Report of the President and Annual Report of the Council of Economic Advisers released...
4:13 PM, Feb 21, 2018  |  BC Extra | Preclinical News

New fluorination method expands medicinal chemistry toolbox

In a paper published in Nature, a group from the Max Planck Institute and Harvard University describe a method to fluorinate a wider array of aromatic carbon-hydrogen bonds than currently available methods allow. The method...
3:41 PM, Feb 21, 2018  |  BC Extra | Company News

CDC panel recommends AZ's FluMist for 2018-19 season

The CDC's Advisory Committee on Immunization Practices (ACIP) voted 12-2 in favor of recommending FluMist Quadrivalent from AstraZeneca plc (LSE:AZN; NYSE:AZN) as an age-appropriate option for flu prevention for the 2018-2019 influenza season, according to...
3:28 PM, Feb 21, 2018  |  BC Extra | Company News

Ipsen seeks to invest in early stage innovation with Arix

Life sciences investment firm Arix Bioscience plc (LSE:ARIX) partnered with Ipsen Group (Euronext:IPN; Pink:IPSEY) to create new companies focused on developing and commercializing "innovative therapies" in undisclosed indications. Arix said it could not provide details...
3:27 PM, Feb 21, 2018  |  BC Extra | Politics & Policy

EU expert panel offers recommendations for innovative pricing models

In response to a request for opinion on innovative pricing models from the European Commission, an expert panel said it is "unlikely that a single payment model will be optimal for all situations." The panel...